Dean Rudge is a journalist whose work has appeared in Informa. He focuses on the pharmaceutical and biotech industries, covering topics such as biosimilars, drug launches, legal disputes, and market trends. With a keen interest in the healthcare sector, Dean provides insightful analysis and reporting on key developments in the industry.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Dean Rudge's coverage predominantly focuses on the healthcare and pharmaceutical industry, with a specific emphasis on pharmaceutical companies, biosimilars, drug market dynamics, and patent issues. His articles mainly provide announcements from the private sector within this industry.
Given his focus on private sector announcements and press releases in the pharmaceutical space, Dean may be particularly interested in pitches that offer exclusive insights or interviews with key figures at pharmaceutical companies regarding new product launches, legal battles over patents or biosimilars, or strategic business moves such as acquisitions or market entries.
Considering the scientific themes present in his coverage attributes along with topics covered like biosimilars and drug markets suggest he might also be open to pitches featuring expert commentary from researchers or professionals who can speak to advancements within these areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Dean Rudge
With sales projected to peak at nearly $700m a year, Galafold – the first oral monotherapy for people living with the ultra-rare genetic disorder Fabry disease – is a lucrative target for ANDA sponsors. However, Teva, which has just put pen to paper on a patent-litigation settlement agreement, will have to wait more than a decade to roll out its generic product.
Trio Of Claimants Come Close But Obviousness Challenge ‘Tainted By Hindsight'
A watershed moment is on the horizon for US biosimilars, with Amgen looking poised to debut competition to Eylea (aflibercept).
By: Dean Rudge
Biosimilar competition to Xolair, one of the largest monoclonal antibodies coming off patent in the middle of this decade, has been pushed back to an unknown date in the US, as Celltrion awaits news from the US FDA on its biosimilar application.
Roche's 2022-launched Vabysmo took no time at all to reach the coveted $1bn in sales, and the originator is continuing to feel optimistic about the newer-generation VEGF brand's prospects, even as Amgen readies the launch of the first US biosimilar to Eylea.
While the firm's mind and money continues to gear towards branded and novel drugs, India's Sun Pharma still maintains a mammoth global generics business, including in the US where Sun saw a healthy leap in sales during its financial second quarter.
By: Dean Rudge
While Roche admits that an acceleration of biosimilar competition to its blockbuster IL-6 inhibitor Actemra/RoActemra is anticipated in the final three months of the year, the Swiss originator has been surprised by the lack of challenge to its franchise so far.
The wait for US competition to AbbVie's Lumigan 0.01% glaucoma brand, launched more than a decade ago, goes on, after Mankind bowed to infringement of a key US patent.
By: Dean Rudge
All eyes are on Eylea, after Amgen said last week that it would launch the first US biosimilar in the face of ongoing litigation. The California-based player has spoken of its prospects in the wet-AMD space, including a desire to chart its own path amid supply shortages for Avastin.
Generics Bulletin previews the most noteworthy and anticipated events for November 2024.
(833) 317-6278 
